Novo and Hims end feud, will sell obesity drugs together

Core Insights - Novo Nordisk A/S is set to sell its weight-loss drugs on Hims & Hers Health Inc.'s platform, marking the end of a legal dispute between the two companies [1][3] - A new partnership announcement is expected soon, following a previous agreement that was terminated by Novo due to Hims marketing copycat medications [2][3] - The partnership is seen as a positive development for Hims, with its shares surging 40% in after-hours trading, while Novo's American depositary receipts rose 2.1% [3][4] Company Developments - Novo Nordisk had previously sued Hims for launching a copycat version of its Wegovy weight-loss pill, accusing Hims of breaching US patents [3] - The partnership indicates that Novo is under pressure to regain market share in the competitive obesity market, where it has been losing ground to competitors like Eli Lilly & Co. [5] - Novo's strategy includes expanding partnerships with telehealth companies to enhance market reach, as seen with its collaborations with Ro and Weight Watchers [6] Industry Context - The telehealth sector has seen companies like Hims capitalize on the opportunity to sell lower-cost alternatives during supply shortages of weight-loss drugs [6] - The FDA has recently indicated plans to address the rise of copycat weight-loss drugs, which may impact the market dynamics [7]